Pre-exposure prophylaxis (PrEP) agents are needed that do not depend on daily or near-daily pill-taking. Long-acting injectable agents have the potential to prevent people from getting HIV without having to take a pill every day.

This is how long-acting Cabotegravir acts as an integrase inhibitor to prevent HIV. Learn more at https://www.hptn.org/research/studies/176.